Datapoint: FDA Approves Lilly’s Interchangeable Insulin

The FDA on Nov. 16 granted Eli Lilly’s Rezvoglar, a biosimilar to Sanofi’s insulin Lantus, interchangeability with its reference product. This approval marks the second interchangeable copy of Lantus — Viatris and Biocon Biologics’ Semglee hit the market in November 2021. For the treatment of type 2 diabetes, Semglee currently holds covered or better status for 60% of all insured lives, to Lantus’ 71%.

SOURCE: MMIT Analytics, as of 11/21/22

0 Comments
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 30

Datapoint: BMS to Battle AstraZeneca in Court Over Yervoy-Imjudo Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today